TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33382529
Drug: 150 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 × 10^6 CAR+ T-cells (high dose)
Study: 33382529
Drug: Lymphodepleting chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting chemotherapy (fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2 daily × 3)
Study: 37233875
Drug: Kukoamine B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kukoamine B 0.06 mg/kg
Study: 37233875
Drug: Kukoamine B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kukoamine B 0.12 mg/kg
Study: 37233875
Drug: Kukoamine B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kukoamine B 0.24 mg/kg
Study: 39607505
Drug: Inhaled mannitol
Normalized name: mannitol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled mannitol
Study: 32707561
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg·kg body weight‐1)
Study: 32707561
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 mg·kg‐1 dextrose)
Study: 34617375
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 μg) added to insulin therapy
Study: 33713208
Drug: Cotton (Bt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotton (Bt RCH‐2) exposed to 200 mg/kg soil Cd
Study: 33713208
Drug: Cotton (Bt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotton (Bt RCH‐2) exposed to 0 mg/kg soil Cd (control)
Study: 33713208
Drug: Cotton (Bt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotton (Bt RCH‐2) exposed to various higher levels of Cd (200, 400, 600, 800, and 1000 mg/kg soil)
Study: 32886536
Drug: Mandatory twice‐weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory twice‐weekly clinical evaluation
Study: 32886536
Drug: Standard once‐weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard once‐weekly clinical evaluation
Study: 33063477
Drug: Aprocitentan 25
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan 25 mg once daily for 10 days
Study: 34331766
Drug: Enhanced physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced physical therapy interventions
Study: 33481341
Drug: Weekly CERA
Normalized name: CERA
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly CERA administration
Study: 33481341
Drug: Biweekly CERA
Normalized name: CERA
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biweekly CERA administration
Study: 34536278
Drug: Visual Art
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visual Art Therapy (VAT) - 12 sessions over 6 weeks
Study: 32665460
Drug: 6-monthly community
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-monthly community distribution points (6MCD)
Study: 36028887
Drug: L-serine (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-serine (3.0 g taken 30 min before bedtime for 2 weeks)
Study: 36028887
Drug: L-serine
Normalized name: L-Serine
DrugBank: Serine (DB00133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-serine
Study: 36028887
Drug: L-serine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-serine and Placebo
Study: 34226572
Drug: Rhamnan sulphate
Normalized name: Potassium sulphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhamnan sulphate (100 mg/day)
Study: 32859235
Drug: Rifampin combination
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin combination therapy with standard antimicrobial treatment (cloxacillin or vancomycin)
Study: 32859235
Drug: Standard antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antimicrobial treatment (cloxacillin or vancomycin) without rifampin
Study: 35803624
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg daily azithromycin
Study: 34213957
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 (170 μg)
Study: 34213957
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D3 (20 μg)
Study: 33471730
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (IA)
Study: 33145864
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day of E. angustifolia fruit powder
Study: 33145864
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day of isomalt + corn starch (placebo)
Study: 34592624
Drug: Adjunct yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunct yoga therapy (YG; n = 35)
Study: 32532144
Drug: Comprehensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive intervention to reduce CVD events including drug therapy, lifestyle changes, and adherence support.
Study: 32409760
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (Control Group C, n=60)
Study: 32409760
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (Control Group C)
Study: 32237945
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (terazosin and nifedipine)
Study: 34849989
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg every 6 months for 24 months
Study: 33260142
Drug: Quinine 1
Normalized name: quinine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 1 (25-ml solution, 2 mM of quinine)
Study: 33260142
Drug: Placebo (25-ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (25-ml sweet-tasting no-carbohydrate solution)
Study: 33260142
Drug: Control (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (25 ml of water)
Study: 32108529
Drug: Microdosing LSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdosing LSD (13 mcg, 11.3% of one tab)
Study: 32108529
Drug: Microdosing psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdosing psilocybin (0.3 g of dried psilocybin mushrooms)
Study: 32751269
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g OBG varying in MW and viscosity
Study: 32751269
Drug: Control (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (200 mL water alone)
Study: 38438123
Drug: Rabies control
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies control vaccine
Study: 33089713
Drug: Active CO2-laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active CO2-laser treatment
Study: 35643855
Drug: Standard-of-care chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care chemotherapy (SoC)
Study: 35027012
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (60% FiO2 and 0.1 µg/kg PGE1)
Study: 35027012
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (40% FiO2 and 0.1 µg/kg PGE1)
Study: 35027012
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (40% FiO2 and 0.2 µg/kg PGE1)
Study: 32559027
Drug: Dextroamphetamine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (2.0 mg/kg, i.p.) in mice
Study: 32559027
Drug: Dextroamphetamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (0.3 mg/kg, p.o.) in humans
Study: 32559027
Drug: Dextroamphetamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (0.3 mg/kg, p.o.)
Study: 32559027
Drug: mGlu5 expression
Approvals — FDA: no, EMA: no, PMDA: no
Description: mGlu5 expression in drug-naïve mice
Study: 33471681
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day prednisone for 1 week followed by 1 week of nonsteroidal anti-inflammatory drugs
Study: 33471681
Drug: 6-week prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-week prednisone therapy
Study: 33188874
Drug: Utidelone plus
Normalized name: Utidelone
DrugBank: Utidelone (DB17575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utidelone plus capecitabine (30 mg/m2 IV daily, days 1-5, over 90 min; capecitabine 1000 mg/m2 orally b.i.d., days 1-14)
Study: 33188874
Drug: Capecitabine alone
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine alone (1250 mg/m2 orally b.i.d., days 1-14)
Study: 33129015
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment + electrotherapy
Study: 33129015
Drug: Only hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Only hormonal treatment (control)
Study: 35691208
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for insomnia (CBTi) - 8 weekly group sessions over 3 months
Study: 33925432
Drug: Saffron extract
Normalized name: saffron extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron extract (15.5 mg per day)
Study: 33185990
Drug: Omecamtiv mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv mecarbil (25 mg, 37.5 mg, or 50 mg twice daily)
Study: 32183741
Drug: Mirabegron (initially
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (initially 25 mg/day, optional increase to 50 mg/day after week 4/8)
Study: 32511749
Drug: Alteplase 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 0.9 mg/kg (maximum 90 mg)
Study: 35296780
Drug: VV116 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: VV116 (oral nucleoside analog)
Study: 34100746
Drug: Tailor‐made notched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailor‐made notched music therapy
Study: 32029012
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly sessions of CBT or IPT
Study: 32029012
Drug: Weekly sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly sessions of CBT or IPT
Study: 34093551
Drug: Nexvax2 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nexvax2 (900 μg, n = 12)
Study: 616191017
Drug: Luseogliflozin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin 2.5 mg once daily for the last 7 days
Study: 34018672
Drug: 1-day continuing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day continuing professional development (CPD) education programme on the International Caries Classification and Management System (ICCMS™) and monthly performance feedback
Study: 32248838
Drug: Biological nurturing
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biological nurturing
Study: 32126317
Drug: Supervised group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised group exercise program (twice weekly for 12 weeks)
Study: 36322381
Drug: Viscosity (gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscosity (gel and liquid)
Study: 32706660
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3D virtual reality and hands-on aromatherapy
Study: 35633354
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g intravenously) given 12 hr. before skin incision (Group 2)
Study: 35633354
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g intravenously) given 12 hr. after operation (Group 3)
Study: 34228855
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) monotherapy for 96 weeks
Study: 32275363
Drug: Medicinal penetration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicinal penetration on acupoint combined with medication (oral prednisone tablets for 40 days, starting with 10 mg three times a day, reducing by 5 mg every 7 days)
Study: 34369837
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 300 mg/day for 8 weeks
Study: 32922107
Drug: Guided imagery-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery-based smoking cessation intervention (details on dosage and duration not available)
Study: 34333826
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (6-fold of MED as initial dose)
Study: 34333826
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose (4-fold of MED as initial dose)
Study: 34333826
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (2-fold of MED as initial dose)
Study: 33333771
Drug: Oral Rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Rehydration Solution (DD) - carbohydrates: 33 g·L‐1, sodium: 60 ± 3 mmol·L‐1
Study: 33333771
Drug: Sports Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports Drink (SD) - carbohydrates: 62 g·L‐1, sodium: 31 ± 3 mmol·L‐1
Study: 36175936
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate Ringer’s solution (BRS)
Study: 36175936
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate Ringer’s solution
Study: 38183121
Drug: Treatment satisfaction
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment satisfaction
Study: 35297463
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group continued daily activities
Study: 34101713
Drug: Hyperbaric prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric prilocaine 50 mg
Study: 34101713
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 10 mg
Study: 33113277
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg, daily)
Study: 33113277
Drug: Sertraline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (100 mg, OD)
Study: 33113277
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg, OD)
Study: 33113277
Drug: Dapoxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine (30 mg, OD)
Study: 32316009
Drug: Neural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural therapy (n = 52)
Study: 32316009
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no neural therapy, n = 61)
Study: 35263859
Drug: Intravenous selenium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous selenium selenite for 5 days
Study: 37943491
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for ≤2 years
Study: 32524500
Drug: Denosumab 120
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 120 mg subcutaneously
Study: 34076068
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (0.5 mg/kg IV) in addition to propofol anesthesia for ECT
Study: 33788463
Drug: Thunder-fire moxibustion
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thunder-fire moxibustion combined with mifepristone (10 mg once a day) for 3 months
Study: 33788463
Drug: Mifepristone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (10 mg once a day) for 3 months
Study: 36219978
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (early‐PN)
Study: 36219978
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (late‐PN)
Study: 36219978
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition intake
Study: 33606931
Drug: Tapentadol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol (50 mg bid)
Study: 33606931
Drug: Oxycodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (10 mg bid)
Study: 35872874
Drug: Dexmedetomidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.4 μg/(kg·h)
Study: 35872874
Drug: Dexmedetomidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.6 μg/(kg·h)
Study: 35872874
Drug: Dexmedetomidine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.8 μg/(kg·h)
Study: 35872874
Drug: Dexmedetomidine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.8 μg/(kg·h) in group A3
Study: 33676882
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids (7-day course) + nasal steroids and douching (12-week course)
Study: 33676882
Drug: Nasal steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal steroids and douching (12-week course)
Study: 33573598
Drug: Oxycodone for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone for PCIA + transmuscular quadratus lumborum block
Study: 33573598
Drug: Oxycodone for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone for PCIA
Study: 32979512
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg on day 1) and nab-paclitaxel (125 mg/m2 on day 1 and day 8, every 3 weeks)
Study: 35525251
Drug: tenecteplase (0·25
Approvals — FDA: no, EMA: no, PMDA: no
Description: tenecteplase (0·25 mg/kg, maximum 25 mg, intravenous bolus over 10 s)
Study: 35525251
Drug: alteplase (0·9
Approvals — FDA: no, EMA: no, PMDA: no
Description: alteplase (0·9 mg/kg, maximum 90 mg, 10% as bolus over 1 min and 90% as infusion over 1 h)
Study: 35231024
Drug: Monthly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly follow-up (n=1,976)
Study: 35231024
Drug: Weekly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly follow-up (n=1,802)
Study: 35231024
Drug: Monthly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly follow-up (n=976)
Study: 35231024
Drug: Weekly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly follow-up (n=1,005)
Study: 35231024
Drug: Monthly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly follow-up (n=1,873)
Study: 35231024
Drug: Weekly follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly follow-up (n=1,721)
Study: 32472590
Drug: TACE alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE alone (monotherapy group)
Study: 34560112
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg each, 2 tablets, total 6 mg)
Study: 33661539
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics
Study: 35723939
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (24-unit dose individualized according to crow's feet line distribution)
Study: 34412104
Drug: Esketamine 84
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 84 mg nasal spray plus standard of care
Study: 34412104
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray plus standard of care
Study: 34861154
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg per day
Study: 32072695
Drug: Nutrilite™ Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrilite™ Multi Carotene supplement
Study: 36441522
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral doses of vitamin D3, 14,000 IU for 3 years
Study: 33998163
Drug: Candesartan 4
Normalized name: candesartan 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 4 mg q.d.
Study: 33998163
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients unwilling to take medication)
Study: 38559896
Drug: Family-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Based Treatment (FBT)
Study: 35325055
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of antibiotics
Study: 35325055
Drug: 24-h course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-h course of antibiotics
Study: 36183567
Drug: Parent-administered intervention
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-administered intervention in NICU
Study: 33036254
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with poziotinib and manidipine
Study: 35259151
Drug: Baseline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline treatment levels for those living with HIV
Study: 34339623
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus trastuzumab (840 mg loading dose, then 420 mg every 3 weeks for pertuzumab; 8 mg/kg loading dose, then 6 mg/kg every 3 weeks for trastuzumab)
Study: 32162420
Drug: Buprenorphine and
Normalized name: Buprenorphine and Naloxone Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine and naloxone co‐formulation (4:1 ratio: buprenorphine 2 mg + naloxone 0.5 mg)
Study: 32162420
Drug: Buprenorphine and
Normalized name: Buprenorphine and Naloxone Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine and naloxone co‐formulation (2:1 ratio: buprenorphine 2 mg + naloxone 1 mg)